Medis QFR® continues to show superiority over standard angiography, after a FU-period of 2 years

In the September 2022 issue of JACC journals (, the FAVOR III China Study Group published a sub-study that was aimed to ascertain whether the beneficial outcomes of QFR® guidance for lesion selection during PCI is affected by diabetes status.  

From the total of 3825 patients enrolled, 1295 (33.9%) had diabetes. The study confirmed that the QFR®-guided strategy consistently reduced the 1-year MAC in both diabetic (6.2% vs 9.6%) and non-diabetic (5.6% vs 8.3%) patients versus standard angiography. Among patients in whom PCI was deferred after QFR®, the 1-year MAC risk was similar in patients with and without diabetes (4.5% vs 6.2%). Conclusions: a QFR®-guided lesion selection strategy improves PCI outcomes compared with standard angiography guidance in patients both with and without diabetes. 

This paper was accompanied by a very constructive Editorial Comment by Dr. Morton Kern and. Dr Arnold Seto. Fig. 1 (, shows that the annual number of publications on QFR® has now surpassed that of iFR, and that a sharp increase in clinical uptake is to be expected, much like what happened with FFR well after 2012, following the FAME and FAME 2 studies. 

Share this article on:


Do you want to learn more about QFR®?

Check out the product page of Medis QFR®, to learn more. If you have any other questions, feel free to reach out to us.

Sign up for our newsletter

Subscribe now to find out more about our solutions, latest publications and future releases.

By providing your information and continuing, you agree to Medis’ Terms of Use and Privacy Policy *